Actively Recruiting
Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Led by Bristol-Myers Squibb · Updated on 2024-11-06
505
Participants Needed
2
Research Sites
214 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
CONDITIONS
Official Title
Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult participants 19 years of age or older
- Diagnosis of moderate-to-severe plaque psoriasis
- Candidate for phototherapy or systemic therapy
- Will begin deucravacitinib according to approved product label
You will not qualify if you...
- Use of deucravacitinib for unapproved therapeutic indications in Korea
- Contraindication to deucravacitinib as specified by Korean ministry of food and drug safety prescribing information
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Local Institution - 0001
Seoul, South Korea, 06234
Withdrawn
2
Novotech Laboratory Korea Co., Ltd.
Seoul, South Korea, 06234
Actively Recruiting
Research Team
B
BMS Study Connect Contact Center www.BMSStudyConnect.com
CONTACT
F
First line of the email MUST contain NCT # and Site #.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here